Top 12 Real-World Evidence (RWE) Vendors for Pharma in 2026

Overview

Real-world evidence has moved from a nice-to-have into the critical path for pharma regulatory and commercial strategy. The global RWE solutions market sits at roughly $2.5 to $3 billion in 2025 and is projected to reach $5 to $7 billion by 2030 at a 15 to 20% CAGR, making it the fastest-growing segment in pharma services. The underlying data and analytics layer (healthcare data, RWD licensing, analytics platforms) is materially larger, around $30 billion in 2024, growing to a projected $74 billion by 2031 at roughly 15% CAGR per industry trackers.

Three structural tailwinds drive the category. First, the FDA’s 2018 RWE Framework, refreshed by the Real-World Evidence Program guidances issued through 2024, created explicit pathways for RWE to support label expansion, external control arms for single-arm trials, and post-approval safety and effectiveness commitments. Published oncology approval examples and FDA-facing use cases have made Flatiron and Aetion credible regulatory-grade reference points. Second, the Inflation Reduction Act (IRA) and payer tightening have raised the bar on HEOR evidence: to defend pricing and formulary positioning, sponsors now need budget impact, treatment pattern, and comparative effectiveness studies that only broad claims and EHR data can power. Third, biotech and specialty launches have shifted toward rare disease and oncology, where randomized comparator data is scarce and RWE is often the only credible evidence source.

The 12 vendors ranked in this guide split across five archetypes: integrated scale platforms (IQVIA, OptumLabs), EHR-primary providers (Flatiron, Truveta, ConcertAI, COTA, TriNetX), claims-primary providers (Komodo Health, Aetion), tokenization and linkage infrastructure (Datavant), genomics-integrated (Tempus), and patient-journey plus DTC attribution (Veeva Crossix, Clarify Health). Most pharma sponsors use at least two of these vendors in parallel because the underlying data types are complementary, not substitutable.

Ranking Methodology

The ranking uses seven criteria weighted toward buyer utility for a pharma sponsor evaluating RWE partners for regulatory, HEOR, medical affairs, or commercial use cases:

1. Pharma customer scale: share of top-20 pharma as paying customers, total active engagements, enterprise logo concentration.
2. Data depth and breadth: covered lives, years of longitudinal history, data types (claims, EHR, molecular, PRO, lab, mortality), and data freshness.
3. Regulatory submission history: FDA, EMA, and PMDA submissions citing vendor data, external control arm precedent, post-approval use.
4. Interoperability and linkage: tokenization capability, MapEnhance-style linkage, API maturity, cloud marketplace presence.
5. Therapeutic area fit: oncology, rare disease, autoimmune, and cardiometabolic depth.
6. Analytics capability: HEOR bench, AI and NLP maturity, self-service cohort tooling, regulatory study design expertise.
7. Independence and conflicts: ownership structure, parent-pharma exposure, payer vertical integration, data neutrality.

Rankings balance these factors against total addressable use case. A vendor best in class for a specific archetype (for example, Tempus for genomics-integrated oncology) can outrank a larger vendor for buyers whose portfolio maps to that archetype. Read the ranking as weighted, not absolute.

RWE Market Context in 2026

Three forces shape the 2026 RWE buying environment.

FDA RWE guidance is now actionable. The 21st Century Cures Act instructed FDA to evaluate expanded use of RWE, and FDA’s 2018 Framework for the Real-World Evidence Program plus subsequent guidance documents (Considerations for the Use of RWD and RWE, Data Standards for Drug and Biological Product Submissions Containing Real-World Data, Submitting Documents Using RWD and RWE) give sponsors a documented path. Oncology has led, with published approval examples using RWE and external-control-style evidence. The knock-on effect: sponsors increasingly scope RWE studies pre-submission with FDA, and vendors with submission track records earn a premium.

IRA and payer pressure raise the HEOR bar. Drug Price Negotiation under the IRA, Part D redesign, and state-level reference pricing make budget impact and comparative effectiveness evidence core to launch economics. Payer P&T committees are asking for real-world outcomes within 12 to 24 months of approval, not 36. This favors vendors who can turn a research question into a refreshed analysis quickly, which is why Komodo’s MapLab, Aetion’s Evidence Platform, and IQVIA’s E360 are investing heavily in self-service.

Specialty and rare disease launches expand RWE utility. When pivotal trials enroll 50 to 300 patients, RWE is often the only way to characterize natural history, unmet need, treatment patterns, and real-world effectiveness. Rare disease launches routinely scope multi-year RWE master agreements that cover pre-launch epidemiology, post-launch safety, and label expansion evidence, often $1 million-plus per year per program.

The competitive response: a wave of vertical consolidation (Roche acquiring Flatiron, Datavant merging with Ciox, Norstella assembling MMIT, Panalgo, Citeline, Evaluate, and Dedham into a unified stack) and a parallel set of independent challengers raising large rounds (Truveta, ConcertAI, Komodo Health, Tempus) to compete with IQVIA on data and AI depth.

The Top 12

1. IQVIA: Global scale and regulatory-grade RWE

IQVIA is the default starting point for any RWE procurement conversation at top-20 pharma. Formed in the 2016 merger of IMS Health and Quintiles, IQVIA reported FY2025 revenue of $16.31 billion and employs roughly 93,000 people across 100-plus countries. Public-company. On RWE, IQVIA runs one of the world’s largest de-identified patient databases: more than 1.2 billion non-identified patient records globally. U.S. assets include LRx (nearly 4 billion prescriptions/year covering 260M-plus patients since 2006), Medical and Institutional Claims covering ~191M patients, Ambulatory EMR at 71M-plus patients, and PharMetrics Plus with 107M-plus closed adjudicated enrollees. MIDAS extends to 77 countries and 693 therapeutic classes. E360 is the self-service RWE platform.

Every top-20 pharma is an IQVIA customer. Signature use cases: external control arms, post-approval safety, treatment pattern analyses, global epidemiology, and integrated analytics bundled with commercial data and CRO services. Pricing is enterprise-only; multi-year master agreements typically sit in the high seven to eight figures annually, with individual studies $500K to $5M-plus.

Limitations: IQVIA’s breadth can mean shallower therapeutic depth than boutique specialists (Flatiron for oncology EHR), and some buyers report slower turnaround than Komodo or Aetion. Integration with commercial and CRO lines creates conflict-of-interest questions for sponsors wanting a pure RWE partner. Vendor profile: /vendor/iqvia.

2. Flatiron Health: Oncology EHR gold standard

Flatiron Health, acquired by Roche in April 2018 for roughly $1.9 billion, is a widely cited oncology RWE incumbent. Founded in 2012 by Nat Turner and Zach Weinberg, Flatiron employs ~1,000 people and runs a two-sided model: OncoEMR (cloud EHR) across 280-plus community oncology clinics and ~800 sites of care, enriched by technology-enabled human abstraction to build research-grade oncology datasets.

Flatiron RWD has been used in published regulatory-support examples spanning label expansion and post-market evidence. Datasets cover millions of patient records across major cancer types, linked to claims, mortality, and Foundation Medicine genomic data (Roche’s other RWE asset). Customers include Roche plus a large set of non-Roche sponsors running oncology RWE through Flatiron. Use cases span external control arms for single-arm trials, post-market effectiveness, label expansion, and pragmatic trial design. Pricing: individual oncology RWE studies $500K to $3M; multi-year access agreements exceed $5M/year for large sponsors.

Limitations: Roche ownership creates conflict-of-interest perception, particularly for head-to-head studies against Roche products. Therapeutic scope is oncology-only. Vendor profile: /vendor/flatiron-health.

3. Aetion: Regulatory-grade RWE specialist

Aetion, founded in 2013 by former Harvard epidemiologists Jeremy Rassen and Sebastian Schneeweiss, is the regulatory-grade RWE specialist built around the Aetion Evidence Platform (AEP). The company has raised $200M-plus and counts the FDA, EMA, Canada’s CADTH, and most top-20 pharma as customers.

Aetion’s differentiator is methodologic rigor: AEP is a validated, auditable platform for causal inference with pre-specified protocols, transparent parameters, and audit trails designed for FDA and EMA submission standards. Aetion has participated in FDA RCT DUPLICATE (replicating randomized trials with RWE) and Sentinel Initiative work. AEP runs on claims, EHR, and tokenized linked datasets from Datavant, Komodo, and other sources; Aetion is typically the analytics layer on someone else’s data.

Use cases: external control arms, post-approval safety, treatment effect heterogeneity, label expansion. Pricing is platform subscription plus per-study fees, typically $500K to $3M for enterprise access and individual regulatory studies.

Limitations: Aetion does not own primary data assets, so sponsors pay for data separately; the platform-plus-data model adds procurement complexity versus IQVIA. Commercial and field-analytics use cases are not Aetion’s focus. Not currently listed in the Rx Almanac vendor directory.

4. Datavant: Tokenization and linkage infrastructure

Datavant, formed by the 2021 merger of Datavant and Ciox Health (valued at ~$7 billion at close), is the dominant privacy-preserving tokenization and RWD linkage infrastructure in U.S. healthcare. Datavant does not primarily sell data; it sells the ability to link disparate datasets (claims, EHR, mortality, lab, consumer, specialty pharmacy, trial) via patient tokens without exposing PHI.

The company supports 500-plus real-world data partners and 70-plus of the top 100 U.S. health systems. Pharma uses Datavant tokens to link internal trial data to external claims or EHR, construct external control arms from multi-source cohorts, and run long-duration outcomes studies no single vendor can support alone.

Use cases: tokenization of sponsor trial datasets, multi-source RWD construction for submissions, health system data delivery, DTC-to-claims linkage. Pricing is transaction- and subscription-based; enterprise agreements with top-20 pharma typically $500K to $3M/year plus per-project tokenization fees.

Limitations: Datavant is infrastructure, not analytics. Sponsors need a downstream analytics partner (Aetion, IQVIA, internal HEOR) to turn linked data into evidence. Data licensing terms often require sponsor-to-source direct contracts, adding legal complexity. Not currently listed in the Rx Almanac vendor directory.

5. Komodo Health: All-payer patient journey

Komodo Health, founded in 2014 by Dr. Arif Nathoo and Web Sun, built the Healthcare Map: 330M-plus unique patient journeys, 16M clinical encounters added daily, 160M closed linkable lives. Sources span FFS Medicare, Medicare Advantage, commercial claims, Medicaid, EHR, and specialty pharmacy data. Komodo has raised $514M including a $220M Series E at a $3.3B valuation (2021), reported ~$200M revenue in 2023, and serves 200-plus life sciences customers including 19 of the top 20 biopharma.

The MapLab suite turns this data into analytics: MapView (pre-built dashboards), MapExplorer (no-code cohort builder), MapLab Enterprise (HEOR environment), and Marmot (healthcare AI engine launched August 2025, demonstrated colorectal cancer disparities analysis across 878,000 patients in ~1 hour versus weeks). MapEnhance adds Invitae and GeneDx genomics, PointClickCare LTC EMR, and Helix whole-exome data on 500,000-plus patients.

Use cases: patient journey mapping for specialty and rare disease, HCP targeting, rare disease epidemiology, longitudinal HEOR. Pricing: $150K to $450K per use case per year; enterprise master agreements in the low to mid seven figures.

Limitations: U.S.-centric, limited global. EHR coverage is narrower than Truveta or Flatiron for chart-level questions. Regulatory submission track record is shallower than IQVIA or Flatiron. Vendor profile: /vendor/komodo-health.

6. ConcertAI: Independent oncology and autoimmune RWE

ConcertAI is the leading independent oncology RWE platform, competing directly with Flatiron on data quality without the Roche conflict. Founded in 2018 as Concerto HealthAI, ConcertAI has raised $230M-plus through Series C at a $1.9B valuation, reported ~$200M FY2024 revenue with 72% recurring, exited FY2024 profitable at mid-teens EBITDA margins, and employs ~1,100 to 1,200 people.

Data foundation is the CancerLinQ network, acquired from ASCO in December 2023: 5.5M-plus multi-modal oncology patient records from 100-plus cancer centers across 10 EMR integrations. Molecular partnerships with Guardant Health, Caris, NeoGenomics, and Foundation Medicine (January 2026 integration covers ~500,000 clinico-genomic cancer patients) create depth no other independent oncology vendor matches. CARAai is the AI platform (oncology-tuned LLMs, digital pathology, NVIDIA NIM). Patient360, RWD360, Precision360, and ACT (launched February 2026, claims 10 to 20 month trial timeline compression) are the productized applications.

ConcertAI serves 75% of top-30 life sciences organizations across 2,000-plus provider settings. Use cases: oncology external control arms, clinico-genomic RWE, trial optimization, post-market effectiveness. Expanding into autoimmune and rheumatology.

Limitations: Oncology-centric; autoimmune expansion is early-stage. Non-oncology scale versus IQVIA or Komodo is limited. Vendor profile: /vendor/concertai.

7. Truveta: Health system EHR consortium

Truveta, launched in 2020 and founded by former Microsoft executive Terry Myerson, is the fastest-growing health system EHR consortium in U.S. RWE. The consortium spans more than 30 U.S. health systems covering over 100 million patients across roughly 900 hospitals and 20,000 clinics, delivering de-identified EHR data including full clinical notes, imaging metadata, and lab results alongside structured fields. Total funding exceeds $300 million from health system partners and outside investors.

Truveta’s differentiator is full clinical note access, which supports NLP-driven phenotyping, outcome adjudication, and deep chart-level research that claims-only vendors cannot replicate. The Truveta Language Model (TLM), launched in 2024 and updated through 2026, enables structured extraction from unstructured clinical notes at scale. Signature pharma customers span oncology, cardiometabolic, neurology, and rare disease; public case studies include GLP-1 effectiveness studies, COVID-19 vaccine safety collaborations with CDC, and oncology biomarker-outcome analyses.

Signature use cases include natural history studies, outcome-adjudicated effectiveness studies, biomarker-stratified analyses, and label expansion support for therapies where chart-level detail drives the evidence question. Pricing is subscription plus per-study, typically $500,000 to $3 million per year at enterprise scale; specific values are directional given that Truveta is private and pricing is customer-specific.

Limitations: Truveta is EHR-primary; claims coverage is via linkage partners, not native. Health system consortium model means coverage skews to health systems in-network, which can introduce geographic and payer mix bias. Regulatory submission track record is growing but shorter than Flatiron or IQVIA. Truveta is not currently listed in the Rx Almanac vendor directory.

8. Tempus: Integrated clinico-genomic oncology

Tempus, founded in 2015 by Eric Lefkofsky and headquartered in Chicago, went public on NASDAQ in June 2024 and reported 2024 revenue of approximately $693 million, growing rapidly. The business splits across Genomics (sequencing and diagnostic testing in approximately 40% of U.S. oncologist offices), Data and Services (RWE licensing to pharma), and AI Applications. Tempus’s integrated clinico-genomic oncology dataset, built from its sequencing footprint plus partnered EHR and claims data, is one of the deepest precision medicine RWD assets globally.

Tempus’s pharma business generates high-growth recurring revenue from pharma data licensing, sponsored research, and clinical trial matching. Signature pharma customers include AstraZeneca, Bayer, GSK, and multiple oncology biotechs. Use cases include biomarker-stratified effectiveness, companion diagnostic development, clinical trial matching and enrollment acceleration, and integrated clinico-genomic RWE for oncology regulatory submissions.

Pricing is typically structured as multi-year data licensing deals ($1 million to $10 million-plus per year at enterprise) plus project-based sponsored research. Tempus’s public filings disclose several multi-hundred-million-dollar pharma data agreements.

Limitations: Oncology-concentrated. The sequencing-derived cohort skews to patients with recent molecular testing, which creates selection bias for non-genomic questions. Public company dynamics (quarterly revenue pressure, margin focus) can affect pricing flexibility. Tempus is not currently listed in the Rx Almanac vendor directory.

9. Veeva Data Cloud and Crossix: DTC attribution and patient journey

Veeva Systems acquired Crossix in November 2019 for roughly $430 million, integrating Crossix’s privacy-safe DTC attribution and patient journey analytics into Veeva’s broader commercial stack. Veeva reported FY2025 revenue of approximately $2.75 billion, with its Data Cloud and Commercial Solutions segments growing rapidly. Crossix operates on 250 million-plus U.S. consumers and links de-identified media exposure data to health outcomes (Rx, medical claims, EHR proxies) for DTC measurement and patient journey analytics.

Crossix’s differentiator is DTC attribution at scale: sponsors can measure whether a DTC campaign drove incremental Rx, adherence, or switching behavior, with privacy-safe linkage that most alternative attribution vendors cannot match. The broader Veeva Data Cloud integrates Crossix data with Veeva OneKey HCP reference data, CRM-derived engagement data, and syndicated Rx data for end-to-end commercial analytics.

Signature use cases include DTC campaign attribution, patient journey segmentation, HCP-patient linkage for co-pay and adherence programs, and launch analytics for specialty and primary care brands. Pricing is subscription plus project work, typically $250,000 to $1.5 million per year per use case at enterprise scale.

Limitations: Crossix is commercial and DTC-focused, not a regulatory RWE provider. Data depth for HEOR, natural history, and external control arm use cases is shallower than IQVIA, Flatiron, or Truveta. Attribution methodology is validated but remains opaque enough that some HEOR teams prefer standalone comparators. Vendor profile: /vendor/veeva-systems.

10. COTA: Oncology abstracted RWD

COTA Healthcare, founded in 2011 by Dr. Stuart Goldberg and Dr. Andrew Pecora, is an oncology-focused RWE vendor built on deep human abstraction of oncology EHR data. COTA has raised more than $90 million across its funding history, including a Series D closed in 2021, and partners with Hackensack Meridian Health and other academic cancer centers for data sourcing.

COTA’s dataset covers millions of abstracted oncology patient records with particular depth in hematology (multiple myeloma, lymphoma, leukemia) and rare oncology. The CNA (Cancer Node) classification system is a proprietary patient-similarity framework used for treatment pattern and outcomes analysis. Signature pharma customers span oncology biotechs and mid-cap oncology sponsors. COTA is part of Komodo Health’s MapEnhance partner network via its Trio Health diagnostics collaboration.

Signature use cases include hematology RWE, oncology treatment pattern studies, external control arms for hematologic malignancies, and patient-similarity cohort construction. Pricing is project-based, typically $250,000 to $2 million per study; subscription tiers exist for multi-year sponsors.

Limitations: Scale is materially smaller than Flatiron or ConcertAI. Therapeutic scope is oncology-only, with strongest depth in heme rather than solid tumors. Regulatory submission track record is shorter than Flatiron. COTA is not currently listed in the Rx Almanac vendor directory.

11. TriNetX: Global clinical research network

TriNetX is the largest global federated clinical research network, connecting more than 300 healthcare organizations across roughly 30 countries and giving pharma sponsors federated query access to de-identified EHR data on 300 million-plus patient records. The company was acquired by Clarivate in 2023 for approximately $450 million, integrating into Clarivate’s Life Sciences and Healthcare segment.

TriNetX’s core use case is clinical trial feasibility, site identification, and cohort scouting: a sponsor can query global EHR data to estimate patient counts for specific inclusion and exclusion criteria, identify high-enrollment sites, and run preliminary cohort analyses before committing to a protocol. Federation means data stays at the health system, which reduces legal friction and enables participation from institutions that would not permit full data export. Beyond feasibility, TriNetX supports observational research, natural history studies, and comparative effectiveness analyses.

Signature pharma customers span most top-20 pharma with clinical development footprints, plus mid-cap biotechs running global trials. Pricing is subscription-tiered ($150,000 to $1 million-plus per year depending on network access and use case breadth) plus per-study project fees.

Limitations: Data depth varies by participating site; TriNetX is a network, not a curated dataset, so quality is heterogeneous. Regulatory submission use is limited compared with Flatiron or Aetion. Federated access model means bulk data export is restricted. TriNetX is not currently listed in the Rx Almanac vendor directory.

12. OptumLabs and Clarify Health: Integrated payer analytics

OptumLabs, the research and innovation arm of Optum within UnitedHealth Group, operates one of the largest integrated claims-plus-EHR datasets in the U.S.: more than 300 million lives of historical claims data plus linked EHR records. OptumLabs provides collaborative research with academic and pharma partners and commercial RWD licensing through Optum Life Sciences. Parent revenue (Optum, including OptumRx, OptumHealth, and OptumInsight) exceeded $250 billion in FY2025, making OptumLabs one of the best-resourced RWE platforms by parent backing.

Clarify Health, funded with $326 million-plus in venture capital across multiple rounds led by KKR and others, operates a payer- and provider-focused analytics platform that links claims and care delivery data to outcomes and cost metrics. Clarify sits more on the HEOR and value-based care boundary than pure pharma RWE but increasingly serves pharma launch analytics, patient journey, and payer contracting use cases.

Signature use cases for OptumLabs include HEOR, health services research, comparative effectiveness studies, and Optum-captive-population studies (the roughly 50 million UnitedHealthcare members plus broader Optum footprint). Clarify’s use cases center on payer contracting analytics, value-based care measurement, and launch performance benchmarking. Pricing is enterprise subscription plus project work, typically $500,000 to $3 million per year at enterprise scale.

Limitations: OptumLabs data reflects Optum’s captive payer population, which introduces selection bias and conflict-of-interest questions for studies touching competing plans or services. Clarify’s pharma RWE track record is newer than incumbents, and scale of pharma-specific data is smaller than IQVIA or Komodo. Neither is currently listed in the Rx Almanac vendor directory.

Comparison Matrix

#	Vendor	Primary Data Type	Pharma Customer Scale	Best-For Use Case	Regulatory Track Record
1	IQVIA	Claims + EHR + Rx + global	Universal top-20	Integrated RWE at scale; global	Deep, multi-decade
2	Flatiron Health	Oncology EHR (abstracted)	20-plus top oncology sponsors	Oncology external control arms	Published regulatory-support examples
3	Aetion	Platform on partner data	FDA, EMA, most top-20	Regulatory-grade causal RWE	RCT DUPLICATE; Sentinel
4	Datavant	Tokenization and linkage	70-plus top-100 health systems; top-20 pharma	Multi-source RWD linkage	Infrastructure for submissions
5	Komodo Health	All-payer claims + linkage	19 of top 20 biopharma	Patient journey, rare disease epi	Growing
6	ConcertAI	Oncology EHR + molecular	75% of top-30 life sciences	Independent oncology RWE	Multiple oncology submissions
7	Truveta	Health system EHR + notes	Growing top-20 footprint	Note-level clinical RWE	Emerging; CDC collaboration
8	Tempus	Genomic + clinical	AstraZeneca, Bayer, GSK, oncology biotech	Clinico-genomic oncology	Oncology submissions
9	Veeva Crossix	DTC media + Rx linkage	Most top-20 commercial teams	DTC attribution, patient journey	Commercial, limited regulatory
10	COTA	Oncology EHR (abstracted)	Oncology biotech plus mid-cap	Hematology RWE	Oncology, limited
11	TriNetX	Federated global EHR	Most top-20 with clinical development	Trial feasibility, cohort scouting	Observational and feasibility
12	OptumLabs + Clarify	Integrated payer analytics	Academic plus pharma	HEOR, payer contracting analytics	HEOR and health services

How to Shortlist RWE Vendors by Launch Use Case

Oncology launch: Lead with Flatiron Health for regulatory-grade external control arms and label expansion. Add ConcertAI for independent oncology RWE and clinico-molecular depth. Add Tempus if precision medicine or companion diagnostic development is core to the program. IQVIA slots in for global oncology data and post-market commitments. Most oncology launches touch three of these four vendors across the product lifecycle.

Rare disease launch: Lead with Komodo Health for all-payer epidemiology and patient identification across the Healthcare Map. Add Aetion for regulatory-grade natural history and external control arm work. Add TriNetX for global cohort feasibility and site identification, especially when patient volumes are small. Datavant is typically embedded for linking sponsor clinical trial data to external claims. IQVIA is the scale fallback when rare disease programs require global regulatory support.

Autoimmune and immunology launch: Lead with ConcertAI (expanding into autoimmune with oncology-grade curation) and Komodo Health (scale across rheumatology, dermatology, gastroenterology claims). Add Flatiron if the program touches oncology-adjacent indications. Truveta adds chart-level detail for outcome adjudication. IQVIA remains the default for global registry and post-approval studies.

Primary care and cardiometabolic launch: Lead with IQVIA (scale and prescriber data) plus Komodo Health (patient journey and payer linkage). Add Truveta for health system EHR depth and note-level outcome work. Add Veeva Crossix for DTC launch attribution. OptumLabs is relevant when the launch economics are payer-sensitive.

DTC-heavy launch (any therapeutic area): Veeva Crossix plus Clarify Health for attribution and segmentation. Layer in Komodo or IQVIA for prescription outcome tie-back. Datavant enables linkage between DTC exposure data and downstream Rx and claims.

Pricing Transparency

The figures below are directional. Actual pricing depends on data scope, exclusivity, study complexity, regulatory intent, and negotiating leverage. Treat these as a procurement starting point, not a quote.

• Project-based RWE studies: $250,000 to $2 million per study. Includes most single-question HEOR analyses, external control arms, treatment pattern studies, and label expansion support.
• Subscription data feeds: $500,000 to $5 million per year. Includes longitudinal claims access (Komodo, Datavant-sourced), oncology EHR subscriptions (Flatiron, ConcertAI), and self-service analytics platform licenses (IQVIA E360, MapLab).
• Enterprise integrated analytics agreements: $1 million to $10 million-plus per year. Multi-year master service agreements with IQVIA, Flatiron, ConcertAI, or Komodo that bundle data access, analytics platform, study execution capacity, and dedicated account teams.
• Regulatory-grade external control arm study: $1 million to $5 million per study. Includes protocol development, data acquisition (often multi-source via Datavant), analytics platform (Aetion or similar), and statistical methodology work.
• Tokenization infrastructure: $200,000 to $1 million-plus per year. Datavant and similar vendors, scaling with volume of tokens and number of linkage partners.

Buyers should expect 10 to 30% annual price increases on subscription data feeds and should negotiate multi-year agreements with fixed annual steps. Exclusivity clauses (for example, exclusive oncology EHR access) typically add 30 to 100% pricing premium and are rarely granted by major vendors.

Related Articles

• Data & Analytics Platforms: IQVIA vs Komodo Health vs Definitive Healthcare vs ConcertAI
• Market Access Consulting Firms Comparison
• Pharma Services Market Sizing (2026)
• Hub Services Market Analysis
• Oncology Launch Vendor Playbook
• Pharma Services Explained: Hub, Specialty Pharmacy, and FRM

Category Pages

• Data & Analytics
• Market Access
• Medical Affairs